<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793490</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 12/2021</org_study_id>
    <nct_id>NCT04793490</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Ganglion Block for Management of Post- Dural Puncture Headache in Obstetric Patients</brief_title>
  <official_title>Efficacy and Efficiency of Sphenopalatine Ganglion Block for Management of Post-dural Puncture Headache in Obstetric Patients-A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the efficacy and efficiency of sphenopalatine ganglion&#xD;
      block for management of post dural puncture headache in obstetric patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and objectives: Post dural puncture headache(PDPH) is a common complication of&#xD;
      lumbar puncture, it is likely due to the loss of cerebrospinal fluid into the epidural space&#xD;
      through the dural tear. The prevalence of PDPH is higher in pregnant women.Sphenopalatine&#xD;
      ganglion block (SPGB) is a non-invasive intervention with minimal adverse effects, it is&#xD;
      indicated in acute and chronic facial/head pain like cluster headache, trigeminal neuralgia,&#xD;
      post herpetic neuralgia and pain due to head and neck cancer.SPGB can be performed by&#xD;
      different approaches:transnasal,transoral ,sub zygomatic and lateral infratemporal.Transnasal&#xD;
      is the easiest, least invasive approach which can be done at bedside.&#xD;
&#xD;
      The objective of this trial is to study the efficacy and efficiency of sphenopalatine&#xD;
      ganglion block for management of post-dural puncture headache in obstetric patients.The&#xD;
      following will be recorded: pain score will be assessed using the numeric rating pain&#xD;
      scale(NRS),heart rate and mean arterial pressure, onset and duration of analgesia, total dose&#xD;
      of ketorolac, duration of hospital stay and patient satisfaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating pain score</measure>
    <time_frame>First 24 hours after the procedure</time_frame>
    <description>Numeric rating pain score will be used to assess the efficacy of SPGB for treatment of PDPH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total analgesic consumption</measure>
    <time_frame>First 24 hours after the procedure</time_frame>
    <description>total dose of ketorolac will be calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Post-Dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Group A (Control group)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive paracetamol 1 g thrice daily intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Sphenopalatine ganglion block group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive sphenopalatine ganglion block via transnasal approache by a cotton tipped applicator soaked in 2%lignocaine with 4 mg dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sphenopalatine ganglion block</intervention_name>
    <description>Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone</description>
    <arm_group_label>Group B (Sphenopalatine ganglion block group)</arm_group_label>
    <other_name>SPGB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>patients will receive paracetamol 1 g thrice daily intravenously</description>
    <arm_group_label>Group A (Control group)</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients ASA I or II post caesarean section&#xD;
&#xD;
          -  Body weight between 60-100 kg&#xD;
&#xD;
          -  Active PDPH within days after spinal anesthesia not relieved with standard treatment&#xD;
             such as, intravenous fluids, bed rest and caffeine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal to participate in the study&#xD;
&#xD;
          -  Body mass index &gt;35kg/m2&#xD;
&#xD;
          -  Patients with :coagulopathy ,nasal septal deviation,polyp&#xD;
&#xD;
          -  History of nasal bleeding&#xD;
&#xD;
          -  Allergy to local anesthetic&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwa M Mowafi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa M Mowafi, MD</last_name>
    <phone>01001320734</phone>
    <phone_ext>002</phone_ext>
    <email>drmarwamostafa@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rehab A Abdelrazik, MD</last_name>
    <phone>01110108610</phone>
    <phone_ext>002</phone_ext>
    <email>rehab.fattah2002@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abassia</state>
        <zip>11591</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Marwa M Mowafi, MD</last_name>
      <phone>01001320734</phone>
      <phone_ext>002</phone_ext>
      <email>drmarwamostafa@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Rehab A Abdelrazik, MD</last_name>
      <phone>01110108610</phone>
      <phone_ext>002</phone_ext>
      <email>rehab.fattah2002@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Marwa Mostafa Mohamed Ali Mowafi</investigator_full_name>
    <investigator_title>Lecturer of anesthesia ,principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Sphenopalatine ganglion block</keyword>
  <keyword>Post-Dural Puncture Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

